Sharmin, S. Et Al. 2021. Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts. CNS DRUGS , vol.35, no.11 , 1217-1232.

Sharmin, S., Lefort, M., Andersen, J. B., Leray, E., Horakova, D., Havrdova, E. K., ... Alroughani, R.(2021). Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts. CNS DRUGS , vol.35, no.11, 1217-1232.

Sharmin, Sifat Et Al. "Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts," CNS DRUGS , vol.35, no.11, 1217-1232, 2021

Sharmin, Sifat Et Al. "Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts." CNS DRUGS , vol.35, no.11, pp.1217-1232, 2021

Sharmin, S. Et Al. (2021) . "Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts." CNS DRUGS , vol.35, no.11, pp.1217-1232.

@article{article, author={Sifat Sharmin Et Al. }, title={Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts}, journal={CNS DRUGS}, year=2021, pages={1217-1232} }